Dalia Dawoud
Dalia Dawoud holds MSc in Economic Evaluation in Health Care (City University London) and PhD in pharmaceutical policy and economics (King’s College London) and has practised as health economist and researcher for over 20 years. Her work has largely focused on the application of health economics and outcomes research (HEOR) in HTA and clinical guidelines. Prior to joining Cytel Inc., she worked at leading organisations including NICE, where she was the founding Associate Director of NICE HTA Innovation Laboratory (HTA Lab) with projects including AI in economic modelling and the evaluation of dementia treatments. She also led a portfolio of HORIZON Europe projects, such as HTx, SUSTAIN HTA and EDiHTA, with combined funding of over 5 million euros.
She is widely published in the areas of HEOR, HTA and pharmaceutical policy and practice. Dalia serves as Associate Editor of ISPOR journal Value in Health and as Director on ISPOR Board of Directors (2023-2026). She is also a member of ISPOR AI Working Group, Living HTA Working Group and ISPOR Task Force on using GenAI in systematic reviews.